TSHA · Taysha Gene Therapies, Inc.

Taysha Gene Therapies Inc Is A Clinical-Stage Biotechnology Company Focused On Advancing Aav-Based Gene Therapies For The Treatment Of Severe Monogenic Diseases Of The Central Nervous System, Or Cns. The Company'S Clinical Program Tsha-102 Is In Development For The Treatment Of Rett Syndrome, A Rare Neurodevelopmental Disorder With No Approved Disease-Modifying Therapies That Address The Genetic Root Cause Of The Disease. The Company Views Its Operations And Manages Its Business As A Single Operating Segment, The Gene Therapy Segment, Which Is The Business Of Developing Aav-Based Gene Therapies For The Treatment Of Rare Monogenic Diseases Of The Central Nervous System.